News

INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the U.S. It is approved for the treatment of: adult

The drug is being developed and commercialized jointly by Regeneron Pharmaceuticals and Teva Pharmaceutical Industries. Under a separate deal with Regeneron, Mitsubishi Tanabe Pharma has exclusive development and

FOP is an extremely rare, serious disease in which an accumulation of heterotopic ossification (HO, extraskeletal bone) in muscle and soft tissue progressively restricts movement by locking joints

CDRD and Zucara are working in partnership to develop unique compounds that will lead to a new safe and effective long-term therapeutic approach as the first once-daily therapeutic

Eravacycline is a novel antibiotic candidate with potent activity against multidrug-resistant (MDR) pathogens, including carbapenem-resistant enterobacteriaceae (CRE), Acinetobacter baumannii, and colistin-resistant bacteria carrying the mcr-1 gene, that is

Following the enrollment of the initial nine patients in the study, the company suspended dosing of patients after observing increases in alanine aminotransferase (ALT) levels that crossed a

Prurigo nodularis (PN), a severely pruritic dermatological condition characterized by itchy skin papules and nodules, has significant impact on quality of life and has no approved therapies. Trevi

The company, located in the Pharma Valley of Nanjing's High-Tech Zone which can be easily accessed within one hour from Shanghai by high-speed train, announced the fundraising today.

The site will house VBL's local biological drugs manufacturing facility, as the company plans ahead for potential commercialization of VB-111. The site design enables modular expansion of the